US EditionRwanda Welcomes News of HIV Preventive Drug to Be Offered At Low Cost
The Clinton Foundation and partners secured a deal to provide the injectable HIV drug Lenacapavir for $40 per year in 120 low- and middle-income countries, increasing access to prevention.
10 Articles
10 Articles
Rwanda Welcomes News of HIV Preventive Drug to Be Offered At Low Cost
Lenacapavir, a Long-acting injectable drug used to prevent HIV, will be made available for $40 a year in over 120 low- and middle-income countries, under a new agreement announced this week between its manufacturer, Gilead, and philanthropic organizations.
Landmark Deals Drop New Injectable PrEP From $28,000 to $40—for Some
Lenacapavir, the new long-acting HIV prevention medication that hit the United States market with a price tag of over $28,000 per patient per year, will be made available for around $40 for 120 low- and middle-income countries and territories. That price puts the medication on par with other forms of pre-exposure prophylaxis (PrEP), but it will be restricted to places included in voluntary generic licensing agreement set by manufacturer Gilead S…
This promising treatment for low- and middle-income countries requires only two injections per year.
Since 2027 Lenacapavir, the new long-acting antiretroviral, will be available in 120 low and middle-income countries. Unitaid, CHAI, Wits RHI and Dr. Reddy's sign an understanding that promises to change the history of the fight against Hiv, aligning the price to that of oral therapies
This antiretroviral has achieved exceptional results in the prevention of HIV, in just two injections per year. Its manufacturer initially marketed it at a price of $28,218.
Coverage Details
Bias Distribution
- 43% of the sources lean Left, 43% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
